Cargando…

Delayed Signs and Symptoms of Extended Release Guanfacine Overdose in Two Adolescent Patients: Implications of Monitoring on the Psychiatry Unit

Guanfacine is a selective alpha-2a adrenoreceptor agonist that with overdose can cause symptoms ranging from mild sedation to coma, respiratory depression, hyporeflexia, hypotonia, bradycardia, and hypotension. Despite a well-defined and predictable toxidrome, variations can be seen based on multipl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mishra, Sanskriti, Shekunov, Julia, Derscheid, Della J., Canterbury, Elizabeth A., Leung, Jonathan G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975677/ https://www.ncbi.nlm.nih.gov/pubmed/35371580 http://dx.doi.org/10.1155/2022/2149301

Ejemplares similares

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended‐release tablets
por: Inoue, Yuji, et al.
Publicado: (2019)

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents
por: Bello, Nicholas T
Publicado: (2015)

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
por: Huss, Michael, et al.
Publicado: (2015)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga, Jose, et al.
Publicado: (2015)

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment
por: Huss, Michael, et al.
Publicado: (2016)

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
por: Joseph, Alain, et al.
Publicado: (2017)

Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial
por: Stein, Mark A., et al.
Publicado: (2015)

Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
por: Sikirica, Vanja, et al.
Publicado: (2012)

Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments
por: Hoang, Karen, et al.
Publicado: (2022)

Attention deficits following ADEM ameliorated by guanfacine
por: Singh-Curry, Victoria, et al.
Publicado: (2010)

Effect of Enteral Guanfacine on Dexmedetomidine Use in the ICU
por: Fetters, Megan B., et al.
Publicado: (2022)

Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology
por: Sikirica, Vanja, et al.
Publicado: (2013)

Once-daily treatment of ADHD with guanfacine: patient implications
por: Strange, Brandon C
Publicado: (2008)

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein
por: Gillis, Nancy K, et al.
Publicado: (2011)

T47. GUANFACINE AUGMENTATION OF ATTENTIONAL FUNCTIONING IN THE SCHIZOPHRENIA SPECTRUM
Publicado: (2020)

A Retrospective Analysis of Guanfacine for the Pharmacological Management of Delirium
por: Jiang, Shixie, et al.
Publicado: (2023)

A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice
por: van Stralen, Judy, et al.
Publicado: (2021)

A computational psychiatry approach identifies how alpha-2A noradrenergic agonist Guanfacine affects feature-based reinforcement learning in the macaque
por: Hassani, S. A., et al.
Publicado: (2017)

Dantrolene Administration in the Management of the Prehospital Patient with Methylenedioxymethamphetamine Overdose: A Case Series and Literature Review
por: Nikoomanesh, Kia, et al.
Publicado: (2022)

Low Fluctuation of Symptoms May Delay Diagnosis of Myasthenia Gravis: A Case Series
por: Dragusin, Andreea, et al.
Publicado: (2021)

Guanfacine for the Treatment of Cognitive Disorders: A Century of Discoveries at Yale
por: Arnsten, Amy F.T., et al.
Publicado: (2012)

Stressing the potential of guanfacine as a treatment for cocaine use disorder
por: Lustberg, Daniel, et al.
Publicado: (2020)

Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions
por: Fukuyama, Kouji, et al.
Publicado: (2021)

Guanfacine as an effective drug for the treatment of tic disorder. Case report
por: Del Sol Calderon, P., et al.
Publicado: (2021)

Delayed presentation of paracetamol overdose
por: Els, Johnre Retief, et al.
Publicado: (2020)

Catatonia in Patients with Dementia Admitted to a Geriatric Psychiatry Ward
por: Sharma, Puja, et al.
Publicado: (2017)

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”
por: Erder, M. Haim, et al.
Publicado: (2013)

Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada
por: Lachaine, Jean, et al.
Publicado: (2019)

Efficacy and safety of guanfacine extended‐release in Japanese adults with attention‐deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double‐blind, placebo‐controlled study
por: Naya, Noriyuki, et al.
Publicado: (2020)

Extended release potassium salts overdose and endoscopic removal of a pharmacobezoar: A case report
por: Guillermo, Pérez Tuñón Jorge, et al.
Publicado: (2014)

Use of combinatorial pharmacogenomic testing in two cases from community psychiatry
por: Fields, Eve S, et al.
Publicado: (2016)

Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD
por: Lachaine, Jean, et al.
Publicado: (2016)

Brief assessment of negative dysmorphic signs
por: Fiori, Patrizia, et al.
Publicado: (2010)

The Relationship of Mentorship to Career Outcomes in Academic Psychiatry and Psychology: a Needs Assessment
por: Sim, Leslie A., et al.
Publicado: (2022)

Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
por: Alsayouf, Hamza A, et al.
Publicado: (2020)

Opioid Overdose Prevention Toolkit Released
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ud5s4ut5p2697l8a20v3nvbqeb